An Open Label, Phase II Study of Amprenavir/Ritonavir or Saquinavir/Ritonavir in HIV-Infected Subjects Following Failure With Kaletra (Lopinavir/Ritonavir) as Their Second Protease Inhibitor.

Abbott103 个研究点分布在 9 个国家目标入组 16 人开始时间: 2001年4月最近更新: 2006年7月28日

适应症

试验速览

阶段: 2 期
状态: 已完成
发起方: Abbott
入组人数: 16
试验地点: 103
主要终点: Proportion of subjects with plasma HIV RNA levels below the limit of quantification (400 copies/mL) at week 24 and the time until loss of virologic response through week 48

研究概览研究设计入排标准结局指标研究者研究点记录与标识符相似试验

研究概览

简要总结

The purpose of this study is to study the safety and efficacy of Amprenavir/ritonavir or saquinavir/ritonavir in HIV infected patients that have failed Kaletra as their second protease inhibitor based HAART.

研究设计

研究类型: Interventional
分配方式: Non Randomized
干预模型: Parallel
主要目的: Treatment
盲法: None

入排标准

年龄范围: 18 Years 至 —（Adult, Older Adult）
性别: All
接受健康志愿者: 否

入选标准

未提供

排除标准

未提供

结局指标

主要结局

Proportion of subjects with plasma HIV RNA levels below the limit of quantification (400 copies/mL) at week 24 and the time until loss of virologic response through week 48

次要结局

未报告次要终点

研究者

发起方

Abbott

申办方类型

Industry

研究点 (103)

Loading locations...

相似试验

已完成

2 期

Amprenavir/Ritonavir, Saquinavir/Ritonavir or Efavirenz in HIV-Infected Subjects Following Failure With Kaletra (ABT-378/Ritonavir) as Their First Protease Inhibitor Based HAARTHIV Infections

NCT00038532Abbott24

已完成

3 期

GEMINI Study - A Study of Saquinavir/Ritonavir in Treatment-Naive Patients With HIV-1 InfectionHIV Infections

NCT00105079Hoffmann-La Roche337

已完成

1 期

To Evaluate the Effect of Ritonavir or Omeprazole on the Pharmacokinetics of Samatasvir (IDX719) in Healthy Participants (MK-1894-006)Chronic Hepatitis C Infection

NCT01813552Merck Sharp & Dohme LLC24

撤回

2 期

A Study Exploring an Induction-Maintenance Kaletra-Based Therapy Versus a Sustiva-Based Regimen in Previously Non-Treated, HIV-1/HCV Co-Infected SubjectsHIV InfectionHepatitis C

NCT00121017Abbott200

已完成

3 期

Tipranavir/Ritonavir vs. Genotypically Defined Protease Inhibitor/Ritonavir in HIV Patients (RESIST-2)HIV Infections

NCT00144170Boehringer Ingelheim882